FDA expands Bravecto Quantum tick label for dogs

Merck Animal Health has won an FDA label expansion for Bravecto Quantum, adding 12-month treatment and control claims in dogs for the Asian longhorned tick and Gulf Coast tick. The March 18, 2026 update extends the product’s reach against two species that matter to veterinarians tracking shifting parasite geography, while keeping Bravecto Quantum positioned as a veterinarian-administered, long-duration option in canine ectoparasite prevention. (merck-animal-health-usa.com)

That expansion builds on Bravecto Quantum’s original FDA approval on July 10, 2025. At launch, the injectable fluralaner suspension became the first FDA-approved flea and tick drug for dogs to provide 8 to 12 months of protection, depending on tick species. The original label covered fleas for 12 months, plus black-legged tick, American dog tick, and brown dog tick for 12 months, with lone star tick coverage limited to 8 months. FDA also stressed that the product must be prescribed by a licensed veterinarian, both because it is injected in-clinic and because veterinarians need to determine whether the appropriate retreatment interval is 8 or 12 months based on likely tick exposure. (fda.gov)

Under the expanded label, Bravecto Quantum now carries 12-month claims for Asian longhorned tick, Gulf Coast tick, black-legged tick, American dog tick, and brown dog tick after a single veterinarian-administered injection. The product remains indicated to kill adult fleas and prevent flea infestations in dogs and puppies 6 months of age and older. Merck framed the update as a response to an evolving parasite landscape, particularly as Asian longhorned and Gulf Coast ticks continue to spread or gain clinical relevance in more areas. (merck-animal-health-usa.com)

The background on Asian longhorned tick helps explain why this label change stands out. USDA APHIS describes the species as an invasive tick that can create heavy infestations, and notes that U.S. populations can reproduce without mating, a trait that supports rapid establishment and spread. USDA and ARS materials also note the tick has been found on domestic animals, including dogs, in the United States. Gulf Coast tick brings a different concern set: it has long been recognized in veterinary literature as the likely vector of Hepatozoon americanum, the agent associated with American canine hepatozoonosis. Taken together, those species-specific risks make broader labeled coverage more relevant than a routine line extension. (aphis.usda.gov)

Merck’s announcement was promotional, but there is also a note of caution in the surrounding market conversation. Earlier this month, BBB National Programs’ National Advertising Division said Merck had support for the claim that Bravecto Quantum is “a safe, effective way to protect dogs year round,” but recommended that the company modify or discontinue certain claims implying that one injection universally provides a full year of tick protection. The reason is the same one FDA highlighted at approval: dogs with potential exposure to lone star ticks still need an 8-month dosing interval. Merck said it would appeal portions of that decision. (bbbprograms.org)

Why it matters: For veterinary teams, the practical value here is twofold. First, the label expansion gives clinics a stronger on-label option for pet parents seeking lower-friction parasite prevention, especially where adherence to monthly or every-12-week products is inconsistent. Second, it sharpens the need for region-specific parasite risk assessment. “Once yearly” is accurate for some tick exposures, but not all. Practices will still need clear protocols for counseling pet parents about local species prevalence, travel history, and when an 8-month revisit is needed because of lone star tick risk. FDA’s own safety communication also remains relevant: isoxazolines are widely used, but the class has been associated with neurologic adverse reactions in some dogs and cats. (fda.gov)

There’s also a competitive angle. Companion animal parasiticide makers have been racing to add label claims tied to emerging or expanding tick threats, including Asian longhorned tick. In that context, Bravecto Quantum’s expanded label strengthens Merck’s differentiation around long duration and in-clinic administration, particularly for practices that see compliance as a medical and business issue, not just a convenience issue. That said, the injectable format means uptake will still depend on case selection, client education, and confidence in aligning the dosing interval with real-world exposure. (elanco.com)

What to watch: The next signals will be whether veterinary practices in emerging tick regions begin using the expanded claims more actively in prevention protocols, and whether Merck’s marketing language changes as the NARB appeal process plays out. (bbbprograms.org)